Skye Bioscience and Redx Pharma Merge to Form Fibrosis-Focused Fibrx Therapeutics

Key Facts

1Skye Bioscience and Redx Pharma agreed to merge to form a new fibrosis-focused company named Fibrx Therapeutics.

2The combined company secured $125 million in financing commitments from healthcare institutional investors.

3The new entity will focus on the RXC008 program for Crohn's disease, with Phase 2 data expected in H2 2028.

In a move reflecting the accelerating pace of biotech consolidation, Skye Bioscience and Redx Pharma have agreed to merge to form a new entity named Fibrx Therapeutics. According to reports, the combined company will specialize in fibrosis treatments, primarily focusing on the RXC008 program for fibrostenotic Crohn's disease. The merger aims to consolidate resources and expertise to accelerate clinical research in this specialized therapeutic area.

The new entity received strong backing from financial markets, securing $125 million in financing commitments from healthcare institutional investors. The combined company is expected to trade on the Nasdaq, providing a broader platform for growth and capital access. This strategic move ensures the financial runway required to support the long-term research demands inherent in the biotechnology sector.

Looking ahead, investors are awaiting Phase 2 data for the RXC008 program, which is anticipated in the second half of 2028. With instrument price data unavailable as of August 14, 2026, market focus remains on the clinical timeline. Traders are also monitoring broader US economic sentiment following recent inflation and CPI data releases, which influence the overall appetite for the high-growth biotech sector.

Sources:

globenewswire.com